Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma.

NCT02549651 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02549651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02549651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
July 13, 2016
Completion date
February 4, 2019
Enrollment
32 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma